AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03739736 — intervention group
Intervention type: OTHER
Intervention: Combination of TB/HIV prevention activities (arm B)
Description: The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
Study NCT03739736 — intervention group
Intervention type: OTHER
Intervention: Standard of care (arm C)
Description: The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm.
Study NCT04456608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
Study NCT05045248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraclonidine Hcl 0.5% Oph Soln
Description: Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
Study NCT03159702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200 cGy on Day: -1
Study NCT03076008 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: No intervention
Study NCT04343521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeted Indoor Residual Spraying (TIRS)
Description: Spraying of insecticide Actellic 300CS will start in May or June extending for 1 to 2 months. Residents will be asked to temporarily leave the house during treatment and wait half an hour to one hour for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed by the Centers for Disease Control and Prevention (CDC), Emory University, and the Universidad Autónoma de Yucatán.
Study NCT03841617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyrogen
Description: intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
Study NCT03841617 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-131
Description: therapeutic dose administered orally to treat thyroid cancer at Week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/ SPECT is performed; then administered once annually, if the patient needs to be re-treated
Study NCT03841617 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I-124
Description: one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
Study NCT03841617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thyroid hormone withdrawal
Description: withdrawal of thyroid hormone during weeks 4 through 8
Study NCT04799704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: swabbing of conjunctiva
Description: Each eye will be sampled with a single, sterile, nylon, flocked swab
Study NCT01154582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg snack
Description: subject consume 4 cooked whole eggs, providing 380 kcal
Study NCT01154582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cottage cheese
Description: Subjects consume 200 g of cottage cheese, providing 380 kcal
Study NCT04551755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin and Doxycycline
Description: 1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes
Study NCT04551755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
Study NCT02359760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Flapless corticotomies
Study NCT03713359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trial arm (MRVAC)
Description: Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
Study NCT03713359 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
Study NCT03804697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective anticoagulation
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
Study NCT03804697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective anticoagulation
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
Study NCT03755297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample analysis of patients treated as standard care
Description: Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
Study NCT02781597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
Study NCT02781597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 0.9% normal saline
Study NCT01023932 — intervention group
Intervention type: DEVICE
Intervention: Cochlear Implants
Study NCT03179930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
Study NCT03384095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Description: Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
Study NCT03384095 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
Study NCT03179930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg IV on D1
Study NCT00564772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, lopinavir, ritonavir
Description: 4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
Study NCT03184831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift, implant placement, sole bovine bone
Description: sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
Study NCT03184831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift, implant placement, injectable PRF + bovine bone
Description: sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
Study NCT01727297 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: REVEAL Implantable Cardiac Monitor
Study NCT04546230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Thoracic Epidural Anesthesia
Description: Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure.
Study NCT04546230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
Study NCT02846311 — intervention group
Intervention type: DEVICE
Intervention: Flu Test
Study NCT04437511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Given IV
Study NCT01991691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-based questionnaire
Description: tablet-based patient reported outcomes (TabPRO)
Study NCT02295488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: blood intake for biological sampling during validated desensitization protocol (Alyostall®)
Study NCT02295488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Desensitization protocol (Alyostall®)
Description: Validated desensitization protocol using Alyostall® performed
Study NCT04437511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT04332562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary restriction (salt restriction)
Description: salt restriction for one week after being diagnosed with hypertension
Study NCT01830478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
Study NCT02548741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride (500-mg capsule)
Description: Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
Study NCT02548741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate (placebo)
Description: Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
Study NCT02548741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucometer (One Touch glucometer), strips and lancets
Description: Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
Study NCT02548741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer (One Touch glucometer), strips and lancets
Description: Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
Study NCT02548741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine container for 24-hour urine collection
Description: During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
Study NCT02548741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urine container for 24-hour urine collection
Description: During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
Study NCT02548741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine container for 24-hour urine collection
Description: During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
Study NCT03882723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluated 4 masks used for NIV with mechanical ventilators
Description: Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
Study NCT03039790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV Vaccine
Description: NoV vaccine injection administered.
Study NCT01830478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
Study NCT03060538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.
Study NCT03060538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.
Study NCT00814164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: IV
Study NCT00814164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: IV
Study NCT00814164 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative study
Study NCT00814164 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative Study
Study NCT00814164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative Study
Study NCT01788839 — intervention group
Intervention type: BEHAVIORAL
Intervention: surveys
Description: A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
Study NCT01788839 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
Study NCT01788839 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal ultrasounds
Description: Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
Study NCT02763566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02763566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered orally
Study NCT02763566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered orally
Study NCT02763566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT02763566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly
Study NCT03483610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider Referral
Description: Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
Study NCT03483610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
Study NCT04088409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT04088409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study NCT00002540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00922272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching SPD489 (lisdexamfetamine dimesylate)
Description: oral, once daily
Study NCT02959190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT05164887 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal resection
Description: the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
Study NCT04502823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Management based on sFlt-1/PlGF values
Description: In women allocated to the intervention group, the sFlt-1/PlGF result will be revealed to the investigators that will act according to the results of sFlt/PlGF:~* Fetuses with sFlt-1/PlGF ≥38, elective delivery will be recommended immediately (within 24h) at ≥37 weeks.~* Fetuses with sFlt-1/PlGF \<38 weekly follow up will be recommended and delivery at ≥40 weeks.